Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase I Study of the PKMYT1 Inhibitor RP-6306 in Combination With Carboplatin and Paclitaxel for the Treatment of Recurrent TP53 Ovarian and Uterine Cancer

NCT06107868 is registered in ClinicalTrials.gov with University Health Network, Toronto as lead sponsor.

NCT NCT06107868
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06107868 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase I Study of the PKMYT1 Inhibitor RP-6306 in Combination With Carboplatin and Paclitaxel for the Treatment of Recurrent TP53 Ovarian and Uterine Cancer
Lead sponsor
University Health Network, Toronto
Phase
Phase 1
Overall status
Active, not recruiting
Start date
March 20, 2024
Completion date
September 30, 2026
Enrollment
6 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

advanced cancer, metastatic cancer, recurrent ovarian cancer, recurrent uterine cancer